- Home
- CHRD vs TLX Comparison
CHRD vs TLX Comparison
Compare CHRD & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRD
- TLX
- Stock Information
- Founded
- CHRD 2007
- TLX 2015
- Country
- CHRD United States
- TLX Australia
- Employees
- CHRD N/A
- TLX N/A
- Industry
- CHRD Oil & Gas Production
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- CHRD Energy
- TLX Health Care
- Exchange
- CHRD Nasdaq
- TLX Nasdaq
- Market Cap
- CHRD 6.7B
- TLX 5.8B
- IPO Year
- CHRD 2010
- TLX N/A
- Fundamental
- Price
- CHRD $111.67
- TLX $19.50
- Analyst Decision
- CHRD Buy
- TLX Strong Buy
- Analyst Count
- CHRD 13
- TLX 1
- Target Price
- CHRD $173.08
- TLX $22.00
- AVG Volume (30 Days)
- CHRD 843.7K
- TLX 18.8K
- Earning Date
- CHRD 02-25-2025
- TLX 01-01-0001
- Dividend Yield
- CHRD 9.09%
- TLX N/A
- EPS Growth
- CHRD N/A
- TLX N/A
- EPS
- CHRD 18.95
- TLX 0.09
- Revenue
- CHRD $4,448,171,000.00
- TLX $484,687,790.00
- Revenue This Year
- CHRD $41.83
- TLX N/A
- Revenue Next Year
- CHRD N/A
- TLX N/A
- P/E Ratio
- CHRD $5.89
- TLX $209.40
- Revenue Growth
- CHRD 20.68
- TLX 80.92
- 52 Week Low
- CHRD $107.24
- TLX $14.01
- 52 Week High
- CHRD $190.23
- TLX $20.00
- Technical
- Relative Strength Index (RSI)
- CHRD 43.54
- TLX N/A
- Support Level
- CHRD $109.12
- TLX N/A
- Resistance Level
- CHRD $115.78
- TLX N/A
- Average True Range (ATR)
- CHRD 3.26
- TLX 0.00
- MACD
- CHRD 0.41
- TLX 0.00
- Stochastic Oscillator
- CHRD 49.22
- TLX 0.00
About CHRD Chord Energy Corporation
Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.